Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from C4 Therapeutics ( (CCCC) ).
C4 Therapeutics has appointed Steve Hoerter to its Board of Directors, highlighting the company’s commitment to advancing its pipeline of targeted protein degraders. Hoerter, with over 30 years of experience in oncology commercialization, previously transformed Deciphera Pharmaceuticals into a global organization. His expertise is expected to guide C4T in becoming a fully integrated biotechnology company, enhancing its innovative approach to addressing unmet needs in cancer treatment.
Find detailed analytics on CCCC stock on TipRanks’ Stock Analysis page.